S14 Fig. CXCR3⁺ and CCR6⁺ memory and naive T regulatory cell responses to treatment. (A) Absolute frequency of CXCR3⁺ mTreg (% CD4 T cells) across the five dose groups. (B) A linear model describes the dose response best with the maximum percentage increase from baseline of CXCR3⁺ mTreg in each participant over the 7 days following treatment shown (average baseline CXCR3⁺ mTreg 2.03 % SE= 0.11 range = 0.94-3.68, N=35). (C) Pre-treatment absolute frequencies at day 0 and response of CXCR3⁺ nTreg (% CD4 T cells) following a dose of Proleukin (baseline 0.13 % (0.01) 0.01-0.5, N=35). (D) Absolute frequencies of CCR6⁺ mTregs (% CD4⁺ T cells). (F) Dose response of CCR6⁺ mTreg to Proleukin over the 7 days following treatment (baseline CCR6⁺ mTreg 2.99 % (0.14) 1.7-5.84, N=37). (E) Absolute CCR6⁺ nTreg (% CD4 T cells) frequencies following treatment (baseline 0.14 % (0.02) 0-0.87, N=37). (G) Increased CXCR3 mean fluorescence intensity (MFI) on mTreg following treatment. (H) Dose-dependent increase in CXCR3 expression on mTregs over the 7 days following treatment (baseline 2252 MFI (45.08) 1783-3193, N=35). (I) Increased expression of CCR6 on mTregs (baseline average 1542 MFI (30.58) 1114-2014). (J) A cubic dose-response model describes the increase in expression of CCR6 on mTregs best in the 7 days following treatment. [Black lines show the mean values for each dose group while the grey lines show the individual participants. The shaded area presents the 95% confidence interval of the fitted model]